Spiromide Tablets 20Mg (1 Strip = 10 Tablets)

Treatment with Lasilactone necessitates regular medical supervision. Particularly careful monitoring is necessary in patients with hypotension or patients liable to electrolyte deficiency. Where indicated, steps is advised to be taken to correct hypotension or hypovolaemia before commencing therapy.
Regular monitoring of serum sodium, potassium, creatinine and glucose is generally recommended during therapy; particularly close monitoring is required in patients at high risk of developing electrolyte imbalances or in case of significant additional fluid loss (e.g. due to vomiting, diarrhoea or intense sweating). Hypovolaemia or dehydration as well as any significant electrolyte and acid-base disturbances must be corrected. This may require temporary discontinuation of Lasilactone.
dministration of Lasilactone is advised to be avoided in the presence of a raised serum potassium. Frequent checks of the serum potassium level are necessary in patients with impaired renal function and a creatinine clearance below 60 ml/min per 1.73 m2Â body surface area as well as in cases where Lasilactone is taken in combination with certain other drugs (e.g. triamterene, amiloride, potassium supplements or non-steroidal anti-inflammatory drugs) which may lead to an increase in potassium levels.